CA2814828C - Method of treatment for mental disorders - Google Patents
Method of treatment for mental disorders Download PDFInfo
- Publication number
- CA2814828C CA2814828C CA2814828A CA2814828A CA2814828C CA 2814828 C CA2814828 C CA 2814828C CA 2814828 A CA2814828 A CA 2814828A CA 2814828 A CA2814828 A CA 2814828A CA 2814828 C CA2814828 C CA 2814828C
- Authority
- CA
- Canada
- Prior art keywords
- fauc
- pharmaceutically acceptable
- adhd
- lurasidone
- acid addition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41108110P | 2010-11-08 | 2010-11-08 | |
| US61/411,081 | 2010-11-08 | ||
| JP2011-033453 | 2011-02-18 | ||
| JP2011033453 | 2011-02-18 | ||
| PCT/JP2011/062314 WO2012063513A1 (en) | 2010-11-08 | 2011-05-24 | Method of treatment for mental disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2814828A1 CA2814828A1 (en) | 2012-05-18 |
| CA2814828C true CA2814828C (en) | 2019-09-10 |
Family
ID=46020227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2814828A Active CA2814828C (en) | 2010-11-08 | 2011-05-24 | Method of treatment for mental disorders |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US8258139B2 (https=) |
| EP (1) | EP2638038A4 (https=) |
| JP (2) | JP5855670B2 (https=) |
| CN (1) | CN103180315A (https=) |
| CA (1) | CA2814828C (https=) |
| WO (1) | WO2012063513A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103565776A (zh) * | 2012-07-25 | 2014-02-12 | 天津市汉康医药生物技术有限公司 | 一种稳定的鲁拉西酮胶囊药物组合物 |
| WO2014192868A1 (ja) * | 2013-05-30 | 2014-12-04 | 大日本住友製薬株式会社 | 環状アミノメチルピリミジン誘導体 |
| US10272080B2 (en) | 2013-09-13 | 2019-04-30 | Florida State University Research Foundation, Inc. | Selective dopamine D4 receptor agonists for treatment of working memory deficits |
| JP6594351B2 (ja) | 2014-06-16 | 2019-10-23 | ジョンソン、マッセイ、パブリック、リミテッド、カンパニー | 新規中間体を含むアルキル化アリールピペラジン及びアルキル化アリールピペリジン化合物の製造方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| DK36291D0 (da) | 1991-03-01 | 1991-03-01 | Lundbeck & Co As H | Anvendelse af piperidylsubstituerede indolderivater til behandling af kognitive lidelser |
| GB9202915D0 (en) | 1992-02-12 | 1992-03-25 | Wellcome Found | Chemical compounds |
| IL110011A (en) | 1994-06-13 | 2004-09-27 | Yeda Res & Dev | Pharmacological preparations for the treatment of schizophrenia |
| WO1996014297A1 (en) | 1994-11-04 | 1996-05-17 | Sumitomo Pharmaceuticals Company, Limited | Novel lactam derivatives |
| JP3775823B2 (ja) | 1995-06-09 | 2006-05-17 | 大日本住友製薬株式会社 | 新規なイミド誘導体 |
| US5688798A (en) * | 1995-10-10 | 1997-11-18 | Hoffmann-La Roche Inc. | Pyrimidine compounds |
| EP1073432B1 (en) | 1998-04-14 | 2007-08-15 | The General Hospital Corporation | Use of d-serine or d-alanine for treating schizophrenia |
| JP2000281576A (ja) | 1999-03-29 | 2000-10-10 | Sumitomo Pharmaceut Co Ltd | イミド誘導体を含有するプロテオグリカン生成促進剤 |
| AR027134A1 (es) | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de indol. |
| CA2422044A1 (en) | 2000-09-14 | 2002-03-21 | Gliatech, Inc. | Nitrogen-containing compounds and their use as glycine transport inhibitors |
| JP4868695B2 (ja) | 2000-09-22 | 2012-02-01 | 大日本住友製薬株式会社 | 崩壊性が良好な経口製剤 |
| CA2431041A1 (en) | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
| EP1395257A1 (en) | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| JP4568463B2 (ja) | 2001-11-05 | 2010-10-27 | 独立行政法人科学技術振興機構 | ドレブリンａ発現抑制動物神経細胞及び非ヒトモデル動物 |
| JP4175800B2 (ja) | 2001-11-27 | 2008-11-05 | 住友化学株式会社 | イミド誘導体の製造方法 |
| EP1480629A1 (en) | 2002-02-08 | 2004-12-01 | Abbott Laboratories | Combination therapy for treatment of schizophrenia |
| EP1535616B1 (en) | 2002-08-22 | 2009-05-13 | Dainippon Sumitomo Pharma Co., Ltd. | Remedy for integration dysfunction syndrome |
| KR101113630B1 (ko) | 2003-06-23 | 2012-02-13 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 노인성 치매 치료제 |
| US20070160537A1 (en) | 2004-02-20 | 2007-07-12 | Takeo Ishiyama | In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia |
| US7122683B2 (en) * | 2004-11-23 | 2006-10-17 | Pfizer Inc. | Amides useful as monoamine re-uptake inhibitors |
| US8283352B2 (en) * | 2005-06-13 | 2012-10-09 | Dainippon Sumitomo Pharma Co., Ltd. | Solubilization preparation |
| TW200812993A (en) | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| CN101663308A (zh) | 2006-10-30 | 2010-03-03 | 桑尔克斯药品公司 | N-甲基色胺钙五水合物(dcp)和基于它的治疗方法 |
| CA2682494C (en) * | 2007-04-04 | 2011-10-11 | Merck & Co., Inc. | Hexahydro-1h-4,7-methanoisoindole-1,3-dione compounds for treating psychiatric disorders |
| JP2008135074A (ja) | 2008-02-25 | 2008-06-12 | Fujitsu Ltd | 情報公開方法および情報公開装置 |
-
2011
- 2011-05-23 US US13/113,703 patent/US8258139B2/en active Active
- 2011-05-24 CN CN2011800528248A patent/CN103180315A/zh active Pending
- 2011-05-24 WO PCT/JP2011/062314 patent/WO2012063513A1/en not_active Ceased
- 2011-05-24 JP JP2013537287A patent/JP5855670B2/ja active Active
- 2011-05-24 CA CA2814828A patent/CA2814828C/en active Active
- 2011-05-24 EP EP11840252.8A patent/EP2638038A4/en not_active Withdrawn
-
2012
- 2012-07-20 US US13/555,044 patent/US9259423B2/en active Active
-
2015
- 2015-12-09 JP JP2015240067A patent/JP6470164B2/ja active Active
-
2016
- 2016-01-13 US US14/995,044 patent/US10098875B2/en active Active
- 2016-01-13 US US14/994,939 patent/US9827242B2/en active Active
-
2018
- 2018-09-24 US US16/139,647 patent/US20190022091A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190022091A1 (en) | 2019-01-24 |
| US9827242B2 (en) | 2017-11-28 |
| JP6470164B2 (ja) | 2019-02-13 |
| US20120115879A1 (en) | 2012-05-10 |
| US8258139B2 (en) | 2012-09-04 |
| US20160129000A1 (en) | 2016-05-12 |
| JP2013541582A (ja) | 2013-11-14 |
| US20160193205A1 (en) | 2016-07-07 |
| JP2016094440A (ja) | 2016-05-26 |
| US10098875B2 (en) | 2018-10-16 |
| US9259423B2 (en) | 2016-02-16 |
| CN103180315A (zh) | 2013-06-26 |
| US20130018056A1 (en) | 2013-01-17 |
| EP2638038A1 (en) | 2013-09-18 |
| CA2814828A1 (en) | 2012-05-18 |
| JP5855670B2 (ja) | 2016-02-09 |
| EP2638038A4 (en) | 2014-03-12 |
| WO2012063513A1 (en) | 2012-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018250214B2 (en) | Methods and compositions for treating aging-associated impairments using CCR3-inhibitors | |
| JP2010510314A (ja) | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 | |
| KR20180022792A (ko) | 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체 | |
| US20190022091A1 (en) | Method of treatment for mental disorders | |
| CN105764510A (zh) | H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途 | |
| CN116075302A (zh) | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 | |
| RU2508106C2 (ru) | Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии | |
| JP2022502441A (ja) | Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物 | |
| CA3111433C (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors | |
| JP5714572B2 (ja) | 精神障害およびその症状の治療のためのｋｃｎｑカリウムチャネル活性の調節方法 | |
| ES3062815T3 (en) | Compositions for treating aging-associated impairments using ccr3-inhibitors | |
| HK40092010A (zh) | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 | |
| RU2508096C2 (ru) | Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии | |
| EA041892B1 (ru) | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов | |
| HK40019123A (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160520 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250513 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250513 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260423 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260423 |